Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia.
A 21-year-old white male with relapsed acute lymphoblastic leukemia (ALL) developed an invasive Zygomycosis infection 3 weeks after beginning re-induction chemotherapy. Because of the high risk of fatal recurrence of the fungal infection, neither long-term maintenance chemotherapy nor allogeneic hematopoietic stem cell transplant (HSCT) was considered appropriate. Because his ALL blasts expressed CD34 but lacked CD133, he received a CD133 selected autologous graft following high-dose consolidation chemotherapy. The patient survives in remission 19 months after HSCT.
Barfield
R C
RC
Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Raymond.barfield@stjude.org
Hale
G A
GA
Burnette
K
K
Behm
F G
FG
Knapp
K
K
Eldridge
P
P
Handgretinger
R
R
D000071916:AC133 Antigen; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D015703:Antigens, CD / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D000077336:Caspofungin; D002648:Child; D003131:Combined Modality Therapy; D000075202:Contraindications; D003907:Dexamethasone / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D054714:Echinocandins; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D018189:Immunomagnetic Separation; D055666:Lipopeptides; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D010455:Peptides / Q000032:analysis*; D010456:Peptides, Cyclic / Q000627:therapeutic use; D036102:Peripheral Blood Stem Cell Transplantation; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000601:surgery*; D011743:Pyrimidines / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014230:Triazoles / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage; D065819:Voriconazole; D020096:Zygomycosis / Q000150:complications / Q000188:drug therapy
D000071916:AC133 Antigen; D000935:Antifungal Agents; D015703:Antigens, CD; D054714:Echinocandins; D006023:Glycoproteins; D055666:Lipopeptides; C000606023:PROM1 protein, human; D010455:Peptides; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; C068538:liposomal amphotericin B; D014750:Vincristine; C101425:posaconazole; D003907:Dexamethasone; D000666:Amphotericin B; D015122:Mercaptopurine; D001215:Asparaginase; D000077336:Caspofungin; D065819:Voriconazole; D008727:Methotrexate